All In Biotech

Drug Trial Radar · NCT07926711

Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local Application of Triamcinolone Acetonide in the Treatment of Alopecia Areata

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Dow University of Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Brief Summary The goal of this clinical trial is to learn which treatment works better for people with alopecia areata, a condition that causes patchy hair loss. The study will compare two commonly used treatments to see which one leads to better hair regrowth and fewer side effects. The main questions this study aims to answer are: Does injecting triamcinolone acetonide into the skin lead to better hair regrowth than microneedling with topical triamcinolone acetonide? Are there any side effects linked to these treatments? Researchers will compare two groups of participants. One group will receive intralesional injections of triamcinolone acetonide. The other group will receive microneedling followed by the local application of triamcinolone acetonide. The results will be compared to see which treatment works better for alopecia areata. Participants will: Be examined by the research team to confirm the diagnosis of alopecia areata Receive one of the two treatments as part of the study Attend follow-up visits so researchers can check hair regrowth and monitor for side effects

Conditions

  • Alopecia Areata

Interventions

  • Triamcinolone acetonideDrug

    Triamcinolone acetonide will be administered as intralesional injections into the affected scalp areas at four-week intervals, according to standard clinical practice.

  • Microneedling with topical triamcinolone acetonideProcedure

    Microneedling will be performed on the affected scalp areas followed by local application of triamcinolone acetonide at four-week intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hair regrowthTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dow University Hospital, Ojha Campus

    Karachi, Sindh, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.